<DOC>
	<DOCNO>NCT01437059</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics pharmacodynamics single dose ALN-PCS02 subject Elevated LDL-Cholesterol ( LDL-C ) .</brief_summary>
	<brief_title>Trial Evaluate Safety Tolerability ALN-PCS02 Subjects With Elevated LDL-Cholesterol ( LDL-C )</brief_title>
	<detailed_description />
	<criteria>Elevated LDLC &gt; 3.0 mmol/L &lt; 5.7 mmol/L Fasting triglyceride concentration â‰¤2.8 mmol/L Body weight &gt; 60.0 kg ; body mass index ( BMI ) 19.00 kg/m2 &lt; 35.00 kg/m2 Adequate blood count , liver renal function May receive lipid lower drug/agent within 30 day prior screen Nonsmokers least 3 month Women childbearing potential must negative pregnancy test , breast feeding , must use adequate method birth control Males agree use appropriate contraception Willing able comply protocolrequired visit schedule visit requirement provide write informed consent Known hepatitis B surface antigen ( HBsAg ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) infection Multiple drug allergy know sensitivity oligonucleotide History drug abuse and/or alcohol abuse Receiving investigational agent within 3 month prior study drug administration Subjects safety laboratory test result deem clinical significant Investigator ; Received prescription drug within 4 week first dose Subjects donate 500 mL blood within 3 month prior ALNPCS02 placebo administration ; Received megadose vitamin therapy dietary supplement within 4 week prior screen Subjects use prescription drug within 4 week first dose Considered unfit study Principal Investigator Employee family member sponsor clinical study site personnel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>